Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Autonomous Technologies Holding PRK Laser Shipments Until Summit Merger

This article was originally published in The Gray Sheet

Executive Summary

Shipments of LADARVision tracker-assisted excimer laser systems for photorefractive keratectomy are being held until completion of Autonomous Technologies' previously planned merger with PRK laser firm Summit Technology on account of patent litigation concerns, Autonomous says. The October deal is anticipated to close in January.

You may also be interested in...



LADARVision Gets Panel Nod For LASIK Hyperopia Correction With Conditions

Laser-assisted in situ keratomileusis (LASIK) labeling for Autonomous Technologies Corp.' s LADARVision ophthalmic excimer laser system should highlight declining predictability of outcome in patients with a pre-operative manifest refractive spherical equivalance (MRSE) or uncorrected visual acuity (UCVA) greater than +/-4 diopters.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel